Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.: Drug Recall
Recall #D-0466-2024 · 04/09/2024
Class III: Low Risk
Recall Details
- Recall Number
- D-0466-2024
- Classification
- Class III
- Product Type
- Drug
- Recalling Firm
- Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
- Status
- Ongoing
- Date Initiated
- 04/09/2024
- Location
- Tokushima, N/A, Japan
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 108,192/30 count bottles or 7 count blister packs
Reason for Recall
Cross Contamination with Other Products
Product Description
Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13
Distribution Pattern
USA nationwide.
Other Recalls by Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
- Class III: Low Risk 04/09/2024
- Class III: Low Risk 04/09/2024
- Class III: Low Risk 04/09/2024
View all recalls by Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. →
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.